SCHEMBL315206

SCHEMBL315206

Cc1cccc(-c2nnc3n2-c2ccc(Cl)cc2NCC3)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 3/20 0.45
AVPR1A P37288 8/20 0.36
GABRA5 P31644 2/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
TGFBR1 P36897 3/20 0.34
THRB P10828 1/20 0.34
MAPK14 Q16539 1/20 0.34
TNKS O95271 1/20 0.33
TNKS2 Q9H2K2 1/20 0.33
KCNH2 Q12809 1/20 0.33
DRD2 P14416 1/20 0.33
DRD4 P21917 1/20 0.33
DRD3 P35462 1/20 0.33
CCR1 P32246 1/20 0.33
CCR8 P51685 1/20 0.33
MAPK1 P28482 1/20 0.33
LMNA P02545 1/20 0.32
GABRA1 P14867 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL313995 0.87 BRD4 (0.45) BRD4TGFBR1THRBMAPK14TNKS
SCHEMBL314426 0.85 BRD4 (0.48) BRD4AVPR1AKCNH2TACR3
SCHEMBL314194 0.85 BRD4 (0.44) BRD4TGFBR1THRBMAPK14MAPK1
SCHEMBL314365 0.78 TNKS2 (0.40) BRD4AVPR1AGABRA5GABRG2GABRB3
SCHEMBL314133 0.78 TNKS2 (0.40) BRD4AVPR1AGABRA5GABRG2GABRB3
SCHEMBL314713 0.78 TNKS2 (0.40) BRD4AVPR1AGABRA5GABRG2GABRB3
SCHEMBL1347807 0.78 AVPR1A (0.39) BRD4AVPR1AGABRA5GABRG2GABRB3
SCHEMBL313644 0.78 BRD4 (0.43) BRD4AVPR1AGABRA5DRD2DRD4
SCHEMBL314003 0.78 BRD4 (0.43) BRD4MAPK14CNR1
SCHEMBL1347558 0.74 AVPR1A (0.40) BRD4AVPR1AGABRA5GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1966211-B1 TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2012-12-26 EP claimed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US claimed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP claimed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US claimed
EP-1966211-B1 TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2012-12-26 EP disclosed
EP-1966211-B1 TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2012-12-26 EP disclosed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP disclosed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP disclosed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
WO-2007079820-A1 TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306042-A1 Triazole Derivatives TGFBR1, TGFBR2, SMAD3 BRD4 808/4885AVPR1A 3270/4885GABRA5 1063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.